

bioMérieux

General Meeting of Shareholders - May 23, 2024 Answer to a written question from a shareholder

The Board of Directors received a written question asked by a shareholder.

The answer below is given by the Chief Executive Officer, acting on behalf of the Board of Directors, in accordance with the provisions of article L. 225-108 of the French Commercial Code.

Article L. 225-108 paragraph 4 of the French Commercial Code allows the Board of Directors to answer the written questions of shareholders without repeating them at the General Meeting, as long as they appear on the Company's website in a section dedicated to questions and answers

Written question from Varenne Capital (email of May 13, 2024): *"On the topic of major transactions with related parties, could you provide more information to better understand the total charge of € 13,210,349.79? What would be the justification for choosing the Mérieux Institut as a supplier instead of another company? (i.e. cost, technical specialization, other reason). The information provided in the Universal Registration Document does not seem complete enough given the size of the total amount."*

Answer provided: *"The amount of 13.2M€ invoiced by the Institut Mérieux to bioMérieux pays for the following services: representation of bioMérieux and protection of its interests with the French and foreign political and health authorities, scientific support (competitiveness cluster, governance of several scientific entities, medical symposia notably on the challenges of antibiotic resistance) and administrative support (crisis communication, protection and management of the name ...). In addition, this amount includes the re-invoicing of the cost of the internal audit and risk team, which reports directly to the Institut Mérieux, a guarantee of its full independence."*